Previous 10 | Next 10 |
Marinus Pharmaceuticals, Inc. (MRNS) Q3 2022 Earnings Conference Call November 8, 2022 8:30 AM ET Company Participants Sasha Damouni Ellis – Vice President-Corporate Affairs and Investor Relations Scott Braunstein – Chief Executive Officer Christy S...
The following slide deck was published by Marinus Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Marinus Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation
Marinus Pharmaceuticals ( NASDAQ: MRNS ) stock dropped 18% after-hours on Monday after the firm has priced its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75/share, and, to certain investors in lieu ...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price ...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) stock dropped 19% postmarket on Monday after the firm announced an underwritten public offering of its securities. Underwriters will have a 30-day option to buy up to an additional 15% of the number of securities in the off...
Marinus Pharmaceuticals press release ( NASDAQ: MRNS ): Q3 EPS of $1.89 may not be comparable to consensus of $0.02. Revenue of $2.34M (-76.9% Y/Y) misses by $23.42M . Shares -20% . For further details see: Marinus PharmaceuticalsEPS of $1.89, revenue...
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities. All of the securities to be sold in the off...
Initiated U.S. ZTALMY ® (ganaxolone) launch in late July with over 50 completed CDKL5 deficiency disorder prescription enrollment forms; approximately 40% of those patients were on reimbursed therapy by the end of the third quarter ZTALMY generated $0.56 million in net pr...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) is scheduled to announce Q3 earnings results on Tuesday, November 8th, before market open. The consensus EPS Estimate is $0.02 (+103.8% Y/Y) and the consensus Revenue Estimate is $25.76M (+154.8% Y/Y). Over the last 1 year, MRNS...
Marinus Pharmaceuticals ( NASDAQ: MRNS ) has entered into a revenue interest financing agreement with Sagard Healthcare Partners for a total of $32.5M upfront in return for payments based on U.S. net sales of ganaxolone, including the recently approved ZTALMY or...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals , Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of ...
Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Attention Marinus Pharmaceuticals, Inc. ("Marinus" or the "Company") (NASDAQ: MRNS) Investors. A securities fraud class action lawsuit has been filed against Marinus on behalf of purchasers of Marinus securities between March 17, 20...
RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not progressing to IV anesthesia...